Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017

Fig. 2

Daily doses of benzodiazepines and z-hypnotics among patients who discontinued OAT. Legends: CI = Confidence interval, df = degrees of freedom, lowest = lowest equipotency dose, highest = highest equipotency dose, and OAT = opioid agonist therapy. 1) Paired t-test, df = 155, comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 2) Paired t-test, df = 24, comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 3) Paired t-test, df = 32, comparing mean daily dose ≥0 - ≤90 days to ≥90 - < 0 days related to discontinuation. Displays the daily doses of dispensed benzodiazepines and z-hypnotics, in the following period related to the date of the last dispensation of an OAT opioids: 1) 180–90 days before discontinuation (baseline), 2) 90–0 days before discontinuation, and 3) 0–90 days after discontinuation. Discontinuation was defined as all patients on OAT who had the last dispensation of an OAT opioid in the period January 1, 2017, to September 30, 2017, and no dispensation until the end of March 31, 2018. The daily doses were stated in mean, median, 25 percentile, and 75 percentile. An equipotency table for benzodiazepines and z-hypnotics were used to make sensitivity analyses, displaying the lowest equipotency dose and the highest equipotency dose of the included benzodiazepines and z-hypnotics. The results were presented in parentheses. All dispensed benzodiazepines and z-hypnotics were summarized per year

Back to article page